Search results
CVS COVID-19 Vaccine Near Columbus OH
www.cvs.comPharmacy LocationBy appointment only1892 N High Street(614) 298-805155 Graceland Blvd(614) 781-9407109 South High Street Suite 100(614) 224-42613100 Cleveland Avenue(614) 263-0923933 Bethel Road(614) 459-95214777 Sawmill Road(614) 459-76416030 N Hamilton Rd(614) 245-6033Feb 27, 2024 · The vast majority of people experience only minor, temporary side effects such as pain at the injection site, fatigue, headache, or muscle pain — or no side effects at all.
- Overview
- Common side effects
- Potential risk of Guillain-Barré syndrome
- Controversy regarding blood clots
Vaxzevria, the COVID-19 vaccine developed by the University of Oxford and AstraZeneca, may cause some of the mostly mild-to-moderate side effects that people often encounter after any vaccination. However, there are also some recent controversies surrounding rare blood clotting incidents linked to this vaccine.
Coronavirus data
All data and statistics are based on publicly available data at the time of publication. Some information may be out of date. Visit our coronavirus hub for the most recent information on COVID-19.
Was this helpful?
The Oxford-AstraZeneca COVID-19 vaccine — also known as Vaxzevria, as of March 25, 2021 — is a two-dose vaccine jointly developed by the Oxford Vaccine Group and pharmaceutical company AstraZeneca to target the SARS-CoV-2 virus.
Serum Institute of India’s COVID-19 vaccine, called Covishield, is a version of the Oxford-AstraZeneca vaccine that manufacturers in India produce locally.
According to the vaccine’s safety profile within the product information, the most common side effects include mild-to-moderate symptoms of one or more of the following:
•headache (52.6%)
•fatigue (53.1%)
•muscle or joint pain (44% or 26.4%)
•fever (33.6%)
•chills (31.9%)
Due to reports that some people who have received the Oxford-AstraZeneca vaccine have developed Guillain-Barré syndrome, on July 9, 2021 the EMA recommended that a warning be added to the vaccine’s label to reflect this potential risk.
Guillain-Barré syndrome is a neurological disorder characterized by the immune system “misfiring” and mistakenly attacking the myelin sheath — the protective layer that insulates nerve cell endings, called axons. This causes muscle weakness and paralysis.
However, despite the recommendation it issued, the EMA specified that it is not yet able to conclude beyond all doubt that the Oxford-Astra-Zeneca vaccine directly causes this neurological disorder.
“[T]he available data neither confirms nor rules out a possible association with the vaccine,” the EMA noted.
In early March 2021, the Danish Health Authority put vaccination with Vaxzevria on hold following reports of severe cases of blood clots.
The EMA noted that 30 cases of blood clots, or thrombosis, had occurred following Vaxzevria administration to around 5 million people in the European Economic Area. This included one fatal case in Denmark.
In particular, the EMA observed thrombosis cases alongside thrombocytopenia, which is a condition of low blood platelet counts. It also observed multiple types of thrombosis, including unusual cases of cerebral venous sinus thrombosis, which is a rare occurrence of blood clots in the brain.
The EMA’s safety assessment committee concluded on April 7, 2021, that unusual blood clots with low blood platelets should be listed as very rare side effects of Vaxzevria, suggesting a potential causal link.
However, the EMA states that the vaccine’s benefits continue to outweigh the risks by preventing SARS-CoV-2 infection.
According to the MHRA, in the United Kingdom, there had been 79 reports of blood clotting cases with low levels of platelets as of March 31. All of these cases occurred after first dose administration, and 19 were fatal.
Feb 26, 2024 · The study, published in Vaccine, confirmed previously identified rare safety signals for myocarditis and pericarditis after a mRNA vaccine (Pfizer and Moderna) and Guillain-Barré syndrome and cerebral venous sinus thrombosis (CVST) after viral vector vaccines (AstraZeneca).1
Jun 13, 2022 · A very rare adverse event called Thrombosis with Thrombocytopenia Syndrome (TTS), involving unusual and severe blood clotting events associated with low platelet counts, has been reported after vaccination with this vaccine.
Feb 25, 2022 · A very rare but serious side effect linked to the AstraZeneca vaccine - a specific type of blood clot - happens during this phase and is related to the antibodies produced by your immune...
Apr 23, 2021 · The most serious side effects are very rare cases of unusual blood clots with low blood platelets, which are estimated to occur in 1 in 100,000 vaccinated people. People should seek medical assistance if they have symptoms. What data show for age groups and infection rates.
Apr 28, 2021 · According to the AstraZeneca product monograph, more than one in 10 people will experience some of these very common side-effects: Pain or itching at the injection site. Feeling...
